---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-005561"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2024-02-09T23:59:59+00:00"
generated_at: "2026-06-06T05:05:28.603848+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Enveric Biosciences gets Nasdaq extension to meet $2.5M equity requirement by May 20, 2024

## Summary
- Nasdaq granted extension to May 20, 2024 to meet minimum $2,500,000 stockholders' equity requirement.
- If compliance not evidenced by May 20, 2024, Nasdaq may issue delisting notice.
- Additional compliance deadline: filing of periodic report for June 30, 2024; failure may lead to delisting.
- Company states it plans to regain compliance with the equity requirement.

## SEC filing metadata
- accession: 0001493152-24-005561
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2024-02-09T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315224005561/0001493152-24-005561-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315224005561/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-005561
- JSON: https://secwatch.observer/filing/0001493152-24-005561.json
- Plain text: https://secwatch.observer/filing/0001493152-24-005561.txt

## Key facts
- Listing & Compliance Notices
  Enveric Biosciences, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: February 6, 2024, the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Enveric Biosciences, Inc. (the “Company”) that based on the Staff’s review of materials submitted by the Company to Nasdaq, the Staff determined to grant the Company an extension to regain compliance with the minimum stockholders’ equity requirement of at least $2,500,000 as set forth in Nasdaq Listing Rule 5550(b)(1) for continued listing on the Nasdaq Capital Market (the “Stockholders’ Equity Requirement”). The deficiency with respect to the Company’s compliance with the S
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315224005561/0001493152-24-005561-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.